Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Shares Issued: 2015-2025

Historic Shares Issued for Viking Therapeutics (VKTX) over the last 8 years, with Sep 2025 value amounting to $436,000.

  • Viking Therapeutics' Shares Issued fell 82.65% to $436,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 76.60%. This contributed to the annual value of $10.8 million for FY2024, which is 59.77% up from last year.
  • Viking Therapeutics' Shares Issued amounted to $436,000 in Q3 2025, which was down 20.87% from $551,000 recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' Shares Issued registered a high of $5.7 million during Q1 2021, and its lowest value of $5,000 during Q3 2021.
  • For the 3-year period, Viking Therapeutics' Shares Issued averaged around $1.9 million, with its median value being $1.8 million (2024).
  • The largest annual percentage gain for Viking Therapeutics' Shares Issued in the last 5 years was 3,440.00% (2021), contrasted with its biggest fall of 97.57% (2021).
  • Over the past 5 years, Viking Therapeutics' Shares Issued (Quarterly) stood at $66,000 in 2021, then surged by 127.27% to $150,000 in 2022, then rose by 12.00% to $168,000 in 2023, then spiked by 495.24% to $1.0 million in 2024, then plummeted by 82.65% to $436,000 in 2025.
  • Its Shares Issued was $436,000 in Q3 2025, compared to $551,000 in Q2 2025 and $349,000 in Q1 2025.